CHICAGO, August 6, 2015 /PRNewswire/ --

RnRMarketResearch.com adds EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023 market research with forecasts on the diagnosed incident cases of multiple myeloma in the 8MM that are to hit 97225 by 2023.

Complete report on multiple myeloma market epidemiology forecasts spread across 42 pages supported with 14 tables and 6 figures is now available at http://www.rnrmarketresearch.com/epicast-report-multiple-myeloma-epidemiology-forecast-to-2023-market-report.html .

Epidemiologists forecast an increase in the diagnosed incident cases of multiple myeloma market in the 8MM, from 67,557 diagnosed incident cases in 2013 to 97,225 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 4.39% during the forecast period. The five-year diagnosed prevalent cases of multiple myeloma in the 8MM are expected to increase from 168,750 diagnosed prevalent cases in 2013 to 236,866 diagnosed prevalent cases in 2023, with an AGR of 4.04% during the forecast period. The increase in the diagnosed five-year prevalent cases of multiple myeloma is partly attributed to the moderately rising trend in the incidence of multiple myeloma in the 8MM, combined with changes in the population demographics in the respective markets.

This multiple myeloma market epidemiology forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research's (IARC's) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC's Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Strength of this analysis is that epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.

Order a copy of EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023 market research report at http://www.rnrmarketresearch.com/contacts/purchase?rname=401415 .

The Multiple Myleoma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for multiple myeloma in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). The series includes a 10-year epidemiological forecast for diagnosed incident and total prevalent cases of monoclonal gammopathy of undetermined significance (MGUS) cases, segmented by age and sex. It also includes a 10-year forecast for diagnosed incident cases of multiple myeloma, segmented by age (in five-year increments beginning at 40 years and ending at =85 years), sex, and stage at clinical diagnosis, as well as a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of multiple myeloma in these markets. The Multiple Myeloma epidemiology report is written and developed by Masters- and PhD-level epidemiologists. The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma cell. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but multiple myeloma causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins called monoclonal (M) proteins that can impair kidney functions.

The Multiple Myeloma EpiCast series will allow readers to develop business strategies by understanding the trends shaping and driving the global multiple myeloma market, quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plan as well as organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.

The data tables and figures provided in this multiple myeloma in 8MM forecast report include:

MM Clinical Stages at Diagnosis, Using the ISS Criteria

Risk Factors and Comorbidities for MM

Trends in the Age-Adjusted Incidence of MM in the US, Ages ≥40 Years, 1993-2007

Trends in the Age-Adjusted Incidence of MM in the 5EU, Ages ≥40 Years, 1993-2007

Trends in the Age-Adjusted Incidence of MM in Japan, Ages ≥40 Years, 1993-2007

Trends in the Age-Adjusted Incidence of MM in Urban China, Ages ≥40 Years, 1993-2007

Trends in the Five-Year Relative Survival (%) of MM in the 8MM, Both Sexes, 1993-2009

8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Incident Cases

8MM, Sources of Epidemiological Data Used for the Forecast for MM Diagnosed Five-Year Prevalent Cases

8MM, Sources of Epidemiological Data Used for the Segmentation of MM Incident Cases by Clinical Stage at Diagnosis

8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N (Row %), 2013

8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N (Row %), 2013

8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

8MM, Diagnosed Incident Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

8MM, Age-Specific Diagnosed Incident Cases of MM, Both Sexes, N, 2013

8MM, Sex-Specific Diagnosed Incident Cases of MM, Ages ≥40 Years, N, 2013

8MM, Age-Standardized Diagnosed Incidence of MM (Cases per 100,000 Population), Ages ≥40 Years, by Sex, 2013

8MM, Diagnosed Incident Cases of MM by Clinical Stage at Diagnosis, Ages ≥40 Years, N, 2013

8MM, Five-Year Diagnosed Prevalent Cases of MM, Both Sexes, Ages ≥40 Years, N, 2013-2023

On a related note, another research titled Hematological Malignancies: Multiple Myeloma (MM) - Early and Robust Diagnosis along with New Treatment Options can have Considerable Impact on Management of the Disease highlights the emerging new treatments in RRMM /NDMM, which includes combination of small molecules and biologics, and novel approach of molecular analysis of MM.  This report also provides M&A deals in the diagnostic, cancer area along with growing market opportunities. Furthermore, the competitive landscape of NDMM and RRMM is also highlighted.  The rivalry prevalent in the global onco-diagnostic and therapeutic MM market is quite fierce with numerous local and global players contenting for the market share.  On the global diagnostic front, the key players are Roche, Abbott Diagnostics, and Illumina; and in Tx area, the key players are Celgene, Takeda pharma, Amgen, Novartis, and JNJ. Companies like Affymetrix,  SkylineDx, AgenaBio, Signal Genetics, Cancer Genetics Inc, Illumina, NeoGenomics, Exiqon, Regulus Therapeutics, Rosetta Genomics, Sequenta, Takeda Pharma, Celgene, Amgen, On Pharma, Abbott, BMS, Mundipharma, Novartis,MorphoSys, JNJ and Innate Ph are mentioned in this research available at http://www.rnrmarketresearch.com/hematological-malignancies-multiple-myeloma-mm-early-and-robust-diagnosis-along-with-new-treatment-options-can-have-considerable-impact-on-management-of-the-disease-market-report.html .

Explore more reports on the life sciences market at http://www.rnrmarketresearch.com/reports/life-sciences .

About Us:  

RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.

Connect with Us: 

G+ / Google Plus: https://plus.google.com/104156468549256253075/posts

Twitter: https://twitter.com/RnRMR

Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345

RSS / Feeds: http://www.rnrmarketresearch.com/feed

Contact:
Ritesh Tiwari
1 South Dearborn Street,
21st Floor, Chicago,
Illinois, 60603,
United States
Tel: +1-888-391-5441
sales@rnrmarketresearch.com

SOURCE RnR Market Research